India / DCGI approves Covaxin for emergency use in children aged 12-18 years

The DCGI has approved Bharat Biotech’s Covaxin COVID-19 vaccine for emergency use among children aged 12 to 18 years. Covaxin will be administered among children in two doses, with a gap of 28 days between the first and second dose. In October, the Subject Expert Committee (SEC) had recommended the DCGI to allow emergency use of Covaxin among children.

Vikrant Shekhawat : Dec 26, 2021, 08:05 AM
New Delhi: Bharat Biotech's COVID-19 vaccine Covaxin has received approval from the Drugs Controller General of India (DCGI) for emergency use for kids aged between 12-18 years, official sources said.

"Bharat Biotech receives approval from DCGI for emergency use of its vaccine for kids aged between 12-18 years," sources said ANI.

Earlier, Bharat Biotech had submitted data from clinical trials in the 2-18 years age group for COVAXIN (BBV152) to Central Drugs Standard Control Organisation (CDSCO).

The data has been thoroughly reviewed by the CDSCO and Subject Experts Committee (SEC) and has provided their positive recommendations, the vaccine maker had said.